Sort
85,873 grants matching “alzheimers”
MAEVE: Microbiota mediated flavonoid metabolites for cognitive health
$1,520,504Arpana Church · University Of California Los Angeles · R01 · FY2025 · AG
The UCSF Brain Health Assessment for the Detection of Cognitive Impairment Among Diverse Populations in Primary Care
$1,520,402Katherine Laurel Possin · University Of California, San Francisco · UH3 · FY2021 · NS
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects
$1,520,269John Didsbury · T3d Therapeutics, Inc. · R01 · FY2022 · AG
The RAW Brain - The Effect of Rumination, Anxiety and Worry on Aging and Dementia Risk
$1,519,076Carmen Andreescu · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · MH
Translational Evaluation of PET Radiotracers
$1,518,919Robert Innis · National Institute Of Mental Health · ZIA · FY2020 · MH
Emory Alzheimer's Disease Center
$1,518,430Allan I Levey · Emory University · P50 · FY2012 · AG
Mechanisms of youth-associated blood-borne factors regulating CNS rejuvenation
$1,518,274Joseph Michael Castellano · Icahn School Of Medicine At Mount Sinai · RF1 · FY2021 · AG
Perivascular fibroblasts, vascular fibrosis, and their contributions to cerebral amyloid angiopathy
$1,517,868Ethan Lippmann · Vanderbilt University · RF1 · FY2025 · NS
A National Resource for Postmortem Brain Research
$1,517,815Mc Lean Hospital (Belmont, Ma) · R24 · FY2004 · MH
Immunoglobulin Light Chain Fibrillogenesis
$1,517,567Boston University Medical Campus · P01 · FY2003 · HL
Mechanisms of molecular machines that regulate the neuronal cytoskeleton
$1,517,465Antonina Roll-Mecak · National Institute Of Neurological Disorders And Stroke · ZIA · FY2016 · NS
A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
$1,517,441Jeffrey M. Brown · Sensorium Therapeutics Inc · R44 · FY2025 · AG
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD
$1,517,318Douglas R Galasko · University Of California, San Diego · U01 · FY2008 · AG
Discovery of Novel Proteomic Targets for Treatment of Alzheimer's Disease
$1,516,903Allan I Levey · Emory University · U01 · FY2015 · AG
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
$1,516,817D. Martin Watterson · Northwestern University At Chicago · U01 · FY2022 · AG
Health of the Cholinergic System and Risk for Alzheimer's Disease in Postmenopausal Women
$1,516,478Julie A Dumas · University Of Vermont & St Agric College · R01 · FY2019 · AG
ALZHEIMER'S DISEASE RESEARCH CENTER
$1,515,796University Of Kentucky · P50 · FY2003 · AG
CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging
$1,515,754Ann Carolyn McKee · Boston University Medical Campus · U01 · FY2015 · NS
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
$1,515,611Kathleen E. Rodgers · University Of Arizona · U01 · FY2022 · AG
Differential Effects of Exercise Modality on Cognition and Brain in Older Adults
$1,515,398Eric Dennis Vidoni · University Of Kansas Medical Center · R01 · FY2023 · AG
Alzheimers Disease Patient Registry
$1,515,029Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2014 · AG
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions
$1,514,673Sally Temple · Regenerative Research Foundation · U01 · FY2025 · AG
Genetic Epidemiology of Alzheimer's Disease in African Americans
$1,514,612Jennifer Jaie Manly · Columbia University Health Sciences · R01 · FY2010 · AG
Imaging and Analysis Techniques to Construct a Cell Census Atlas of the Human Brain
$1,514,474Bruce Fischl · Massachusetts General Hospital · U01 · FY2020 · MH
Optimization and preclinical development of soluble gamma-secretase modulators for AD
$1,514,460Steven Lee Wagner · University Of California, San Diego · U01 · FY2016 · AG